<SEC-DOCUMENT>0001104659-17-008291.txt : 20170213
<SEC-HEADER>0001104659-17-008291.hdr.sgml : 20170213
<ACCEPTANCE-DATETIME>20170213061809
ACCESSION NUMBER:		0001104659-17-008291
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20170211
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20170213
DATE AS OF CHANGE:		20170213

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			DUPONT E I DE NEMOURS & CO
		CENTRAL INDEX KEY:			0000030554
		STANDARD INDUSTRIAL CLASSIFICATION:	PLASTIC MATERIAL, SYNTH RESIN/RUBBER, CELLULOS (NO GLASS) [2820]
		IRS NUMBER:				510014090
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-00815
		FILM NUMBER:		17595659

	BUSINESS ADDRESS:	
		STREET 1:		974 CENTRE ROAD
		CITY:			WILMINGTON
		STATE:			DE
		ZIP:			19805
		BUSINESS PHONE:		3027741000

	MAIL ADDRESS:	
		STREET 1:		974 CENTRE ROAD
		CITY:			WILMINGTON
		STATE:			DE
		ZIP:			19805
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>a17-4311_18k.htm
<DESCRIPTION>8-K
<TEXT>


<html>
<head>



  </head>
<body link=blue lang="EN-US">
<div style="font-family:Times New Roman;">
<div style="border-bottom:solid windowtext 1.0pt;border-left:none;border-right:none;border-top:solid windowtext 3.0pt;padding:1.0pt 0in 1.0pt 0in;">
<p style="border:none;margin:0in 0in .0001pt;padding:0in;"><font size="1" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="5" face="Times New Roman" style="font-size:18.0pt;font-weight:bold;">UNITED STATES</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="5" face="Times New Roman" style="font-size:18.0pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">WASHINGTON, D.C. 20549</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="5" face="Times New Roman" style="font-size:18.0pt;font-weight:bold;">FORM&nbsp;8-K</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="3" face="Times New Roman" style="font-size:12.0pt;font-weight:bold;">CURRENT REPORT</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="3" face="Times New Roman" style="font-size:12.0pt;font-weight:bold;">PURSUANT TO SECTION&nbsp;13 OR 15(d)&nbsp;OF</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="3" face="Times New Roman" style="font-size:12.0pt;font-weight:bold;">THE SECURITIES EXCHANGE ACT OF 1934</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Date of Report (Date of Earliest Event Reported): <b>February&nbsp;13, 2017 (February&nbsp;11, 2017)</b></font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="5" face="Times New Roman" style="font-size:18.0pt;font-weight:bold;">E. I. du Pont de Nemours and Company</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(Exact Name of Registrant as Specified in Its Charter)</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div align="center">
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;">
<tr>
<td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Delaware</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">1-815</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">51-0014090</font></b></p>    </td>   </tr>
<tr>
<td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(State or Other   Jurisdiction</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(Commission</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(I.R.S. Employer</font></p>    </td>   </tr>
<tr>
<td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Of Incorporation)</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">File Number)</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Identification No.)</font></p>    </td>   </tr>  </table>
</div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">974 Centre Road</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Wilmington, Delaware 19805</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(Address of principal executive offices)</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Registrant&#146;s telephone number, including area code: &#160;<b>(302) 774-1000</b></font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Check the appropriate box below if the Form&nbsp;8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</font></p>
<p style="margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="2" face="Wingdings" style="font-size:10.0pt;">o</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Written communications pursuant to Rule&nbsp;425 under the Securities Act (17 CFR 230.425)</p>
<p style="margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="2" face="Wingdings" style="font-size:10.0pt;">o</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Soliciting material pursuant to Rule&nbsp;14a-12 under the Exchange Act (17 CFR 240.14a-12)</p>
<p style="margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="2" face="Wingdings" style="font-size:10.0pt;">o</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Pre-commencement communications pursuant to Rule&nbsp;14d-2(b)&nbsp;under the Exchange Act (17 CFR 240.14d-2(b))</p>
<p style="margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="2" face="Wingdings" style="font-size:10.0pt;">o</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Pre-commencement communications pursuant to Rule&nbsp;13e-4(c)&nbsp;under the Exchange Act (17 CFR 240.13e-4(c))</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="border-bottom:solid windowtext 3.0pt;border-left:none;border-right:none;border-top:solid windowtext 1.0pt;padding:1.0pt 0in 1.0pt 0in;">
<p style="border:none;margin:0in 0in .0001pt;padding:0in;"><font size="1" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- SEQ.=1,FOLIO='',FILE='C:\JMS\C902336\17-4311-1\task8274750\4311-1-ba.htm',USER='C902336',CD='Feb 13 04:06 2017' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Item 8.01</font></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Other Events</b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><u><font size="2" face="Times New Roman" style="font-size:10.0pt;">Settlement of PFOA Litigation</font></u></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">As previously reported, approximately 3,550 lawsuits have been filed in various federal and state courts in Ohio and West Virginia alleging personal injury from exposure to perfluorooctanoic acid and its salts, including the ammonium salt (&#147;PFOA&#148;), in drinking water as a result of the historical manufacture or use of PFOA at the Washington Works plant outside Parkersburg, West Virginia.&#160; That plant was previously owned and/or operated by the performance chemicals segment of E. I. du Pont de Nemours and Company (&#147;DuPont&#148;) and is now owned and/or operated by The Chemours Company (&#147;Chemours&#148;).&#160; These personal injury lawsuits were consolidated in multi-district litigation in the United States District Court for the Southern District of Ohio (the &#147;MDL&#148;).</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">On February&nbsp;11, 2017, DuPont entered into an agreement in principle with plaintiffs&#146; counsel representing the MDL plaintiffs providing for a global settlement of all cases and claims in the MDL, including all filed and unfiled personal injury cases and claims that are part of the plaintiffs&#146; counsel&#146;s claim inventory, as well as cases that have been tried to a jury verdict (the &#147;Settlement&#148;).&#160; The total settlement amount is $670.7 million dollars in cash, half of which will be paid by Chemours and half paid by DuPont.&#160; DuPont&#146;s payment would not be subject to indemnification or reimbursement by Chemours.&#160; In exchange for that payment, DuPont and Chemours will receive a complete release of all claims by the settling plaintiffs.&#160; The Settlement was entered into solely by way of compromise and settlement and is not in any way an admission of liability or fault by DuPont or Chemours.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The Settlement is not subject to court approval.&#160; The parties have agreed to draft a master settlement agreement to effect the terms of the agreement in principle, which agreement would address the timing and logistics of the settlement payment and conditions under which the Settlement might not proceed, including a walk-away right that enables DuPont to terminate the Settlement if more than a specified number of plaintiffs determine not to participate.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">DuPont and Chemours have also agreed, subject to and following the completion of the Settlement, to a limited sharing of potential future PFOA liabilities (<i>i.e.</i>, &#147;indemnifiable losses,&#148; as defined in the separation agreement between DuPont and Chemours (the &#147;Separation Agreement&#148;)) for a period of five years. During that five-year period, Chemours would annually pay future PFOA liabilities up to $25 million and, if such amount is exceeded, DuPont would pay any excess amount up to the next $25 million (which payment will not be subject to indemnification by Chemours), with Chemours annually bearing any further excess liabilities. After the five-year period, this limited sharing agreement would expire, and Chemours&#146; indemnification obligations under the Separation Agreement would continue unchanged.&#160; Chemours has also agreed that, upon the Settlement becoming effective, it will not contest its liability to DuPont under the Separation Agreement for PFOA liabilities on the basis of ostensible defenses generally applicable to the indemnification provisions under the Separation Agreement, including defenses relating to punitive damages, fines or penalties or attorneys&#146; fees, and waives any such defenses with respect to PFOA liabilities.&#160; Chemours has, however, retained defenses as to whether any particular PFOA claim is within the scope of the indemnification provisions of the Separation Agreement.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><u><font size="2" face="Times New Roman" style="font-size:10.0pt;">Press Release</font></u></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">On February&nbsp;13, 2017, DuPont issued a press release announcing the Settlement and the other matters described in this Current Report on Form&nbsp;8-K.&#160; A copy of the press release is attached hereto as Exhibit&nbsp;99.1 and is incorporated by reference into this Item 8.01.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Cautionary Statement About Forward-Looking Statements</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">This communication contains &#147;forward-looking statements&#148; within the meaning of the federal securities laws, including Section&nbsp;27A of the Securities Act of 1933, as amended, and Section&nbsp;21E of the Securities Exchange Act of 1934, as amended. In this context, forward-looking statements often address expected future business and financial performance and financial condition, and often contain words such as &#147;expect,&#148; &#147;anticipate,&#148; &#147;intend,&#148; &#147;plan,&#148; &#147;believe,&#148; &#147;seek,&#148; &#147;see,&#148; &#147;will,&#148; &#147;would,&#148; &#147;target,&#148; similar expressions, and variations or negatives of these words.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Forward-looking statements by their nature address matters that are, to different degrees, uncertain, such as statements about the consummation of the proposed transaction and the anticipated benefits thereof. Forward-looking statements are not guarantees of future performance and are based on certain assumptions and expectations of future events which may not be realized. Forward-looking statements also involve risks and uncertainties, many of which are beyond the company&#146;s control. Some of the important factors that could cause the company&#146;s actual results to differ materially from those projected in any such forward-looking statements are: fluctuations in energy and raw material prices; failure to develop and market new products and optimally manage product life cycles; ability to respond to market acceptance, rules, regulations and policies</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">2<a name="PB_2_065206_9867"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- SEQ.=1,FOLIO='2',FILE='C:\JMS\C902336\17-4311-1\task8274750\4311-1-ba.htm',USER='C902336',CD='Feb 13 04:06 2017' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">affecting products based on biotechnology and, in general, for products for the agriculture industry; outcome of significant litigation and environmental matters, including realization of associated indemnification assets, if any; failure to appropriately manage process safety and product stewardship issues; changes in laws and regulations or political conditions; global economic and capital markets conditions, such as inflation, interest and currency exchange rates; business or supply disruptions; security threats, such as acts of sabotage, terrorism or war, natural disasters and weather events and patterns which could affect demand as well as availability of products for the agriculture industry; ability to protect and enforce the company&#146;s intellectual property rights; successful integration of acquired businesses and separation of underperforming or non-strategic assets or businesses; and risks related to the agreement entered on December&nbsp;11, 2015, with The Dow Chemical Company (&#147;Dow&#148;) pursuant to which the companies have agreed to effect an all-stock merger of equals, including the completion of the proposed transaction on anticipated terms and timing, the ability to fully and timely realize the expected benefits of the proposed transaction and risks related to the intended business separations contemplated to occur after the completion of the proposed transaction. Important risk factors relating to the proposed transaction and intended business separations include, but are not limited to, (i)&nbsp;the completion of the proposed transaction on anticipated terms and timing, including obtaining regulatory approvals, anticipated tax treatment, unforeseen liabilities, future capital expenditures, revenues, expenses, earnings, synergies, economic performance, indebtedness, financial condition, losses, future prospects, business and management strategies for the management, expansion and growth of the new combined company&#146;s operations and other conditions to the completion of the merger, (ii)&nbsp;the ability of Dow and DuPont to integrate the business successfully and to achieve anticipated synergies, risks and costs and pursuit and/or implementation of the potential separations, including anticipated timing, any changes to the configuration of businesses included in the potential separation if implemented, (iii)&nbsp;the intended separation of the agriculture, material science and specialty products businesses of the combined company post-mergers in one or more tax efficient transactions on anticipated terms and timing, including a number of conditions which could delay, prevent or otherwise adversely affect the proposed transactions, including possible issues or delays in obtaining required regulatory approvals or clearances, disruptions in the financial markets or other potential barriers, (iv)&nbsp;potential litigation relating to the proposed transaction that could be instituted against Dow, DuPont or their respective directors, (v)&nbsp;the risk that disruptions from the proposed transaction will harm Dow&#146;s or DuPont&#146;s business, including current plans and operations, (vi)&nbsp;the ability of Dow or DuPont to retain and hire key personnel, (vii)&nbsp;potential adverse reactions or changes to business relationships resulting from the announcement or completion of the merger, (viii)&nbsp;uncertainty as to the long-term value of DowDuPont common stock, (ix)&nbsp;continued availability of capital and financing and rating agency actions, (x)&nbsp;legislative, regulatory and economic developments, (xi)&nbsp;potential business uncertainty, including changes to existing business relationships, during the pendency of the merger that could affect Dow&#146;s and/or DuPont&#146;s financial performance, (xii)&nbsp;certain restrictions during the pendency of the merger that may impact Dow&#146;s or DuPont&#146;s ability to pursue certain business opportunities or strategic transactions and (xiii)&nbsp;unpredictability and severity of catastrophic events, including, but not limited to, acts of terrorism or outbreak of war or hostilities, as well as management&#146;s response to any of the aforementioned factors. These risks, as well as other risks associated with the proposed merger, are more fully discussed in the joint proxy statement/prospectus included in the registration statement on Form&nbsp;S-4 declared effective by the SEC on June&nbsp;9, 2016 (File No.&nbsp;333-209869), as last amended, (the &#147;Registration Statement&#148;) in connection with the proposed merger. While the list of factors presented here is, and the list of factors presented in the Registration Statement are, considered representative, no such list should be considered to be a complete statement of all potential risks and uncertainties. Unlisted factors may present significant additional obstacles to the realization of forward-looking statements. Consequences of material differences in results as compared with those anticipated in the forward-looking statements could include, among other things, business disruption, operational problems, financial loss, legal liability to third parties and similar risks, any of which could have a material adverse effect on Dow&#146;s or DuPont&#146;s consolidated financial condition, results of operations, credit rating or liquidity. Neither Dow nor DuPont assumes any obligation to publicly provide revisions or updates to any forward-looking statements regarding the proposed transaction and intended business separations, whether as a result of new information, future developments or otherwise, should circumstances change, except as otherwise required by securities and other applicable laws. The company undertakes no duty to publicly revise or update any forward-looking statements as a result of future developments, or new information or otherwise, should circumstances change, except as otherwise required by securities and other applicable laws.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Item 9.01.&#160; Financial Statements and Exhibits.</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(d)&nbsp;Exhibits.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;">
<tr>
<td width="10%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:10.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Exhibit&nbsp;No.</font></b></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="87%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:87.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Exhibit&nbsp;Description</font></b></p>    </td>   </tr>
<tr>
<td width="10%" valign="top" style="padding:0in 0in 0in 0in;width:10.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">99.1</font></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="87%" valign="top" style="padding:0in 0in 0in 0in;width:87.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Press Release dated   February&nbsp;13, 2017</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">3<a name="PB_3_065238_7056"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- SEQ.=1,FOLIO='3',FILE='C:\JMS\C902336\17-4311-1\task8274750\4311-1-ba.htm',USER='C902336',CD='Feb 13 04:06 2017' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">SIGNATURE</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;">
<tr>
<td width="52%" valign="top" style="padding:0in 0in 0in 0in;width:52.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="47%" valign="top" style="padding:0in 0in 0in 0in;width:47.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">E. I. DU PONT DE   NEMOURS AND COMPANY</font></p>    </td>   </tr>
<tr>
<td width="52%" valign="top" style="padding:0in 0in 0in 0in;width:52.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="47%" valign="top" style="padding:0in 0in 0in 0in;width:47.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(Registrant)</font></p>    </td>   </tr>
<tr>
<td width="52%" valign="top" style="padding:0in 0in 0in 0in;width:52.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="47%" valign="top" style="padding:0in 0in 0in 0in;width:47.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="52%" valign="top" style="padding:0in 0in 0in 0in;width:52.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="47%" valign="top" style="padding:0in 0in 0in 0in;width:47.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="52%" valign="top" style="padding:0in 0in 0in 0in;width:52.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="47%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:47.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">/s/ Jeanmarie F.   Desmond</font></p>    </td>   </tr>
<tr>
<td width="52%" valign="top" style="padding:0in 0in 0in 0in;width:52.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="47%" valign="top" style="padding:0in 0in 0in 0in;width:47.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Jeanmarie F.   Desmond</font></p>    </td>   </tr>
<tr>
<td width="52%" valign="top" style="padding:0in 0in 0in 0in;width:52.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="47%" valign="top" style="padding:0in 0in 0in 0in;width:47.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Vice President   and Controller</font></p>    </td>   </tr>  </table>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">February&nbsp;13, 2017</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">4<a name="PB_4_065317_5335"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- SEQ.=1,FOLIO='4',FILE='C:\JMS\C902336\17-4311-1\task8274750\4311-1-ba.htm',USER='C902336',CD='Feb 13 04:06 2017' -->

</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>a17-4311_1ex99d1.htm
<DESCRIPTION>EX-99.1
<TEXT>


<html>
<head>



  </head>
<body link=blue bgcolor="white" lang="EN-US">
<div>
<p align="right" style="margin:0in 0in .0001pt 261.35pt;text-align:right;text-indent:-45.35pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Exhibit 99.1</font></b></p>
<p style="margin:0in 0in .0001pt 261.35pt;text-indent:-45.35pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border:none;border-collapse:collapse;">
<tr>
<td width="50%" valign="top" style="padding:0in 5.4pt 0in 5.4pt;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman"><img width="125" height="53" src="g43111mmi001.gif"></font></p>    </td>
<td width="50%" valign="top" style="padding:0in 5.4pt 0in 5.4pt;width:50.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman"><img width="291" height="50" src="g43111mmi002.gif"></font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;">
<tr>
<td width="53%" valign="top" style="padding:0in 0in 0in 0in;width:53.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="7%" valign="top" style="padding:0in 0in 0in 0in;width:7.48%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Contact:</font></p>    </td>
<td width="39%" valign="top" style="padding:0in 0in 0in 0in;width:39.36%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Dan Turner</font></p>    </td>   </tr>
<tr>
<td width="53%" valign="top" style="padding:0in 0in 0in 0in;width:53.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="7%" valign="top" style="padding:0in 0in 0in 0in;width:7.48%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="39%" valign="top" style="padding:0in 0in 0in 0in;width:39.36%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">302-996-8372</font></p>    </td>   </tr>
<tr>
<td width="53%" valign="top" style="padding:0in 0in 0in 0in;width:53.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="7%" valign="top" style="padding:0in 0in 0in 0in;width:7.48%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="39%" valign="top" style="padding:0in 0in 0in 0in;width:39.36%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">daniel.a.turner@dupont.com</font></p>    </td>   </tr>  </table>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">DuPont Reaches Global Settlement of Multi-District PFOA Litigation</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">WILMINGTON, Del., Feb.&nbsp;13, 2017 &#151; DuPont and plaintiffs&#146; attorneys in the Ohio multi-district litigation (MDL) have jointly agreed to a settlement in principle of the MDL involving about 3,550 lawsuits related to PFOA personal injury claims arising from environmental releases of PFOA (perfluorooctanoic acid and its salts) from the Washington Works plant in West Virginia. The total settlement amount is $670.7&nbsp;million in cash, half of which will be paid by Chemours and half paid by DuPont. Both companies denied any wrongdoing.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">This settlement encompasses all claims pending in the MDL, including those matters for which jury verdicts have been rendered. DuPont discontinued PFOA operations at that plant more than a decade ago.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The settlement agreement is subject to receipt of releases or dismissals, as applicable, from individual plaintiffs, among other conditions.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">To address potential PFOA liabilities that might arise in the future, Chemours and DuPont have agreed that, for a period of five years, Chemours would annually pay PFOA liabilities outside the settlement up to $25 million and, that if such amount is exceeded, DuPont would pay any excess liabilities up to the next $25&nbsp;million, with Chemours annually paying any further excess liabilities. After the five-year period, Chemours indemnification obligations under the Separation Agreement continue unchanged and DuPont has no commitment to fund PFOA costs. Chemours has also agreed, that upon the settlement becoming effective, it will not contest its liability to DuPont under the separation agreement for PFOA costs on the basis of ostensible defenses Chemours believes are generally applicable to the indemnification provisions under the Separation Agreement, including that such costs relate to punitive damages, fines or penalties or attorneys&#146; fees for the same, but has retained defenses as to whether any particular PFOA claim is within the scope of the indemnification provisions of the Separation Agreement.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">DuPont (NYSE: DD) has been bringing world-class science and engineering to the global marketplace in the form of innovative products, materials, and services since 1802. The company believes that by collaborating with customers, governments, NGOs, and thought leaders we can help find solutions to such global challenges as providing enough healthy food for people everywhere, decreasing dependence on fossil fuels, and</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">E. I. du Pont de Nemours and Company</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- SEQ.=1,FOLIO='',FILE='C:\JMS\105733\17-4311-1\task8274761\4311-1-mm.htm',USER='105733',CD='Feb 13 04:33 2017' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">protecting life and the environment. For additional information about DuPont and its commitment to inclusive innovation, please visit&nbsp;http://www.dupont.com.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Forward-Looking Statements: </font></b>This communication contains &#147;forward-looking statements&#148; within the meaning of the federal securities laws, including Section&nbsp;27A of the Securities Act of 1933, as amended, and Section&nbsp;21E of the Securities Exchange Act of 1934, as amended. In this context, forward-looking statements often address expected future business and financial performance and financial condition, and often contain words such as &#147;expect,&#148; &#147;anticipate,&#148; &#147;intend,&#148; &#147;plan,&#148; &#147;believe,&#148; &#147;seek,&#148; &#147;see,&#148; &#147;will,&#148; &#147;would,&#148; &#147;target,&#148; similar expressions, and variations or negatives of these words.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Forward-looking statements by their nature address matters that are, to different degrees, uncertain, such as statements about the consummation of the proposed transaction and the anticipated benefits thereof. Forward-looking statements are not guarantees of future performance and are based on certain assumptions and expectations of future events which may not be realized. Forward-looking statements also involve risks and uncertainties, many of which are beyond the company&#146;s control. Some of the important factors that could cause the company&#146;s actual results to differ materially from those projected in any such forward-looking statements are: fluctuations in energy and raw material prices; failure to develop and market new products and optimally manage product life cycles; ability to respond to market acceptance, rules, regulations and policies affecting products based on biotechnology and, in general, for products for the agriculture industry; outcome of significant litigation and environmental matters, including realization of associated indemnification assets, if any; failure to appropriately manage process safety and product stewardship issues; changes in laws and regulations or political conditions; global economic and capital markets conditions, such as inflation, interest and currency exchange rates; business or supply disruptions; security threats, such as acts of sabotage, terrorism or war, natural disasters and weather events and patterns which could affect demand as well as availability of products for the agriculture industry; ability to protect and enforce the company&#146;s intellectual property rights; successful integration of acquired businesses and separation of underperforming or non-strategic assets or businesses; and risks related to the agreement entered on December&nbsp;11, 2015, with The Dow Chemical Company pursuant to which the companies have agreed to effect an all-stock merger of equals, including the completion of the proposed transaction on anticipated terms and timing, the ability to fully and timely realize the expected benefits of the proposed transaction and risks related to the intended business separations contemplated to occur after the completion of the proposed transaction. Important risk factors relating to the proposed transaction and intended business separations&#160; include, but are not limited to, (i)&nbsp;the completion of the proposed transaction on anticipated terms and timing, including obtaining&#160; regulatory approvals, anticipated tax treatment, unforeseen liabilities, future capital expenditures, revenues, expenses, earnings, synergies, economic performance, indebtedness, financial condition, losses, future prospects, business and management strategies for the management, expansion and growth of the new combined company&#146;s operations and other conditions to the completion of the merger, (ii)&nbsp;the ability of Dow and DuPont to integrate the business successfully and to achieve anticipated synergies, risks and costs and pursuit and/or implementation of the potential separations, including anticipated timing, any changes to the configuration of businesses included in the potential separation if implemented, (iii)&nbsp;the intended separation of the agriculture, material science and specialty products businesses of the combined company post-mergers in one or more tax efficient transactions on anticipated terms and timing, including a number of conditions which could delay, prevent or otherwise adversely affect the proposed transactions, including possible issues or delays in obtaining required regulatory approvals or clearances, disruptions in the financial markets or other potential barriers, (iv)&nbsp;potential litigation relating to the proposed transaction that could be instituted against Dow, DuPont or their respective directors, (v)&nbsp;the risk that disruptions from the proposed transaction will harm Dow&#146;s or DuPont&#146;s business, including current plans and operations, (vi)&nbsp;the ability of Dow or DuPont to retain and hire key personnel, (vii)&nbsp;potential adverse reactions or changes to business relationships resulting from the announcement or completion of the merger, (viii)&nbsp;uncertainty as to the long-term value of DowDuPont common stock, (ix)&nbsp;continued availability of capital and financing and rating agency actions, (x)&nbsp;legislative, regulatory and economic developments, (xi)&nbsp;potential business uncertainty, including changes to existing business relationships, during the pendency of the merger that could affect Dow&#146;s and/or DuPont&#146;s financial performance, (xii)&nbsp;certain restrictions during the pendency of the merger that may impact Dow&#146;s or DuPont&#146;s ability to pursue certain business opportunities or strategic transactions and (xiii)&nbsp;unpredictability and severity of catastrophic events, including, but not limited to, acts of terrorism or outbreak of war or hostilities, as well as management&#146;s response to any of the aforementioned factors. These risks, as well as other risks associated with the proposed merger, are more fully discussed in the joint proxy statement/prospectus included in the registration statement on Form&nbsp;S-4 declared effective by the SEC on June&nbsp;9, 2016 (File No.&nbsp;333-209869), as last amended, (the &#147;Registration Statement&#148;) in connection with the proposed merger. While the list of factors presented here is, and the list of factors presented in the Registration Statement are, considered representative, no such list should be considered to be a complete statement of all potential risks and uncertainties. Unlisted factors may present significant additional obstacles to the realization of forward-looking statements. Consequences of material differences in results as compared with those anticipated in the forward-looking statements could include, among other things, business disruption, operational problems, financial loss, legal liability to third parties and similar risks, any of which could have a material adverse effect on Dow&#146;s or DuPont&#146;s consolidated financial condition, results of operations, credit rating or liquidity. Neither Dow nor DuPont assumes any obligation to publicly provide revisions or updates to any forward-looking statements regarding the proposed transaction and intended business separations, whether as a result of new information, future developments or otherwise, should circumstances change, except as otherwise required by securities and other applicable laws. The company undertakes no duty to publicly revise or update any forward-looking statements as a result of future developments, or new information or otherwise, should circumstances change, except as otherwise required by securities and other applicable laws.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">#&#160;&#160; #&#160;&#160; #</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2/13/17</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">2<a name="PB_2_042615_6592"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- SEQ.=1,FOLIO='2',FILE='C:\JMS\105733\17-4311-1\task8274761\4311-1-mm.htm',USER='105733',CD='Feb 13 04:33 2017' -->

</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g43111mmi001.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g43111mmi001.gif
M1TE&.#=A?0 U '<  "'^&E-O9G1W87)E.B!-:6-R;W-O9G0@3V9F:6-E "P
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M3#(U ")QFI%LG)%R,E)9B9HRLC_UKEV\^NGI%#*J.W4-?ZI"E8'XYB%\-E(
M>C-CM7J7$;4VB&-KH\Z%"FLW/@KD9'WK:A<30D8$LC-/'0+>*&%)$'](;AFM
M:I?*>.<1U7KH'0;*!CC,L@Q+_^TQ2"<*RZL&FC)B)L2HQ&/F0L&(U* ,*E $
MZ)8T(/N1BQF)4)N!CRA5AI:J\$,MTM#E#K^($%-JJW=M*MSX9+9';<US-P1@
MU!AJ"\F0J&@9M$' <XQ#H0M--IK0VAQG578!D!W #T7*&I&J13 *D4=+*SG
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*^]WPCC=% @( .P$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g43111mmi002.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g43111mmi002.gif
M1TE&.#=A(P$R '<  "'^&E-O9G1W87)E.B!-:6-R;W-O9G0@3V9F:6-E "P
M    (P$R (>]&0#%&0#6(0#.&0"]$ "M" "]  #%(0#O[_^M&0"].C'>8W/F
M*0#>$ #>G*WFO<6U8W/FYA#FYISFM1#F6IS..CKF8Q#FC!"U[YRUQ9S>6E*U
MYC&UE.^UYG.UM3&U8^^UM7.UE,ZUYE*U8\ZUM5*EE*6E8Z6M*0CFO9SF[^;6
ME)0Z*=XZK5HZ*5HZ[YPZ:YPZ[QDZ:QDZK9PZ*9PZK1DZ*1D0[]X0:]X0[UH0
M:UH0K=X0*=X0K5H0*5H0[YP0:YP0[QD0:QD0K9P0*9P0K1D0*1EC[]YC:]YC
M[UIC:UICK=YC*=YCK5IC*5IC[YQC:YQC[QEC:QECK9QC*9QCK1EC*1DZSMXZ
M2MXZSEHZ2EHZC-XZ"-XZC%HZ"%HZSIPZ2IPZSADZ2ADZC)PZ")PZC!DZ"!D0
MSMX02MX0SEH02EH0C-X0"-X0C%H0"%H0SIP02IP0SAD02AD0C)P0")P0C!D0
M"!ECSMYC2MYCSEIC2EICC-YC"-YCC%IC"%ICSIQC2IQCSAEC2AECC)QC")QC
MC!EC"!GFE,[>A'OFO=[FA%JUA'.M8Q"MC!#>6C'FYG/FE._FYC'FYKWFM3'F
M8^_FM7/O$#'FYE+F8\[FM5+O.FOFC#&U[[VU.K6UQ;VU$+6UC%*U.I2U$)2E
M.N;6$&NE$.:M.E*]&2G..F/%E)RM6C'FSMZ$[]Z$:]Z$[UJ$:UJ$K=Z$*=Z$
MK5J$*5J$[YR$:YR$[QF$:QF$K9R$*9R$K1F$*1F$SMZ$2MZ$SEJ$2EJ$C-Z$
M"-Z$C%J$"%J$SIR$2IR$SAF$2AF$C)R$")R$C!F$"!G>>XS%8YS%6E+.$#&E
M$"GF.K6M.G/%[^:MC#'O.C&M$'/F$+7%Q>;F.I2E[^:M$%+F$)2EQ>;F.M;F
M$-:EYA"EM1#FUN_%.N;W$&O%$.:M8U+OG)3F.O?F$/?%YA#%M1#%"  Z[^\Z
M:^\Z[VLZ:VLZK>^E.C$Z[\XZ:\XZ[THZ:THZK<[F>ZW%,1"]&0B]" C%&0C6
M.@C." C6(0C.&1 (_P !$!!(<*#!@@@)##@@<*%"@0<(1%R8D*%"A@4=1K1(
M\>+%AA81@H0H\J#$A"@)F!1XLF5"AQTKDO1(,&6"E0<A?APX<B8   ,Z!CV@
MT21,HA,G+AQZ<>A2 4\/-" J "I5J@*05I5Z@&O6J5\/0 T;=F""GP#.HEW+
MMJU;C&X!P'W[$Z/=NEUYUMW+MJM<N7[YQFU[5BU:PX,3*U[,^._:N6@C[B7:
M&'#= 8X9:O;;%>G"K@NS=K6:M>H LF'%CCZMNC19L:$'0Y9[HG+;N9MQ.YX\
M.3!@SGV1_MZ\&'%BW+4?=[[=V#CSVW<[S^:M_*_OR,NEYP7]N3O1[EM9?_^M
M6GJT:]?FO6XM'QJCX>0 \IW(;?EG/K;XT-Z/#V#^@?W\ ? /6@.N!6 ^72%(
MP#\8(7C @)K9]Q.#$=WW(&#WS8=6<AH"D%]_;)UE88&_>4B@?@QUZ*!]";;E
MGWP_:;@?AQ%"^)]<^P$87U<D.EC@A3]]^.! %_+8&8-R,;@0A0^JYL]"_DSE
MCUC_E.:/ %56-64#60[ 8%938DG>E\+1!B!\$B)H87ZU)?!A9+59>"-_.@+
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MS_RK*UPRTI3:(Z;."!&(G1M+F'1U2:@\[Y[]N0\!"M#_# <@0!4JJ$ \\J$
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MVV."FYPE!54ZLGH:K3JGL*6^+Y+!<I+!@AB>(MXSNPE0P$O#\0FN>I0 TGV
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M&Y</+P5CWS5=#P"!:"A@B35W@U-B#Y (")8 -FA;7%8 %= )R\!*-I1]S9
M!> RJ !O9__!3QY'9W[W4EOV: 9P"'/(:V7W@PBF:@P5*?.R*IK3&N&!%%.B
M&@AC%5US'N2Q-:!S'E'C7["3 ,SP9X.%6\&$)^-B"B^U2GI! *T'B'=$?Q6
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M&8_SA@"]F185$ X -70.T)T.$ D/< C__X 8L\00SNB/(;<VQGE2UN5VI\2
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M@[(T!.(]#&+N/.(=ZTI4^K4UXC$FI(C6PR[S67O=LOA1.K:GA))=,/(N  $
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MM^,[[- KC;8"8/CKO3+N-P;Y83\E?-A?"/^\T!I.6_Q!'8S-A0'#.M:QR'+
0.MU)  Q\('4L-D$!! 0 .P$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
